المؤلفون: Saxena, Sarah, Rodts, Christopher, Nuyens, Vincent, Seidel, Laurence, Albert, Adelin, Boogaerts, Jean, Kruys, Véronique, Maze, Mervyn, Vamecq, Joseph

المصدر: British Journal of Anaesthesia. 128(4)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Humans, Mental Status and Dementia Tests, Postoperative Complications, Postoperative Period, high molecular group box 1 protein, inflammation, interleukin-6, mini-mental state examination, perioperative neurocognitive disorders, Anesthesiology, Clinical sciences

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/49r6b0nxTest

المؤلفون: Saxena, Sarah, Rodts, Christopher, Nuyens, Vincent, Lazaron, Juliette, Sosnowski, Victoria, Verdonk, Franck, Seidel, Laurence, Albert, Adelin, Boogaerts, Jean, Kruys, Veronique, Maze, Mervyn, Vamecq, Joseph

المصدر: BMC Anesthesiology. 20(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Behavioral and Social Science, Cardiovascular, Prevention, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Aged, Belgium, Cohort Studies, Female, Geriatric Assessment, Humans, Inflammation, Male, Middle Aged, Neurocognitive Disorders, Preoperative Period, Prospective Studies, Sedentary Behavior, Cognition, High molecular group box 1, Interleukin-6, Perioperative neurocognitive disorders, Medical Physiology, Anesthesiology, Clinical sciences

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/2x68t6jhTest

المؤلفون: P. K. Smith, C. Venter, L. O’Mahony, R. Berni Canani, O. J. L. Lesslar

المصدر: Frontiers in Allergy, Vol 4 (2023)

مصطلحات موضوعية: food allergy, alarmin, advanced glycation end products, receptor for advanced glycation end products (RAGE), high molecular group box 1, carboxymethyllysine (CML), Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/falgy.2023.1148181/fullTest; https://doaj.org/toc/2673-6101Test

الوصول الحر: https://doaj.org/article/fcfa405ca2d548dbb0f1e5b779b8e130Test

المؤلفون: Olga Ciobanu-Caraus, Thomas Czech, Andreas Peyrl, Christine Haberler, Gregor Kasprian, Julia Furtner, Marcel Kool, Martin Sill, Josa M. Frischer, Anna Cho, Irene Slavc, Karl Rössler, Johannes Gojo, Christian Dorfer

المصدر: Cancers, Vol 15, Iss 19, p 4877 (2023)

مصطلحات موضوعية: MB, origin, molecular group, neurosurgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/15/19/4877Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/8e683815539744f2b134cdcde62b38ecTest

المؤلفون: Smith, P K, Venter, C, O'Mahony, L, Berni Canani, R, Lesslar, O J L

المساهمون: Smith, P K, Venter, C, O'Mahony, L, Berni Canani, R, Lesslar, O J L

مصطلحات موضوعية: advanced glycation end product, alarmin, carboxymethyllysine (CML), food allergy, high molecular group box 1, methylglyoxal (MG), receptor for advanced glycation end products (RAGE)

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000994394700001; volume:4; firstpage:1148181; journal:FRONTIERS IN ALLERGY; https://hdl.handle.net/11588/920629Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159906624

الإتاحة: https://doi.org/10.3389/falgy.2023.1148181Test
https://hdl.handle.net/11588/920629Test

المؤلفون: O. G. Zheludkova, L. V. Olkhova, M. V. Ryzhova, L. V. Shishkina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, A. V. Golanov, Yu. Yu. Trunin, N. A. Vorobyov, N. A. Plakhotina, K. F. Boiko, A. S. Levashov, O. B. Polushkina, D. Yu. Korneev, T. V. Postnikova, I. D. Borodina, A. N. Kislyakov, D. A. Skobeev, S. V. Gorbatykh, S. S. Ozerov, E. V. Skorobogatova, E. V. Inyushkina, V. E. Popov, M. V. Mushinskaya, S. G. Kovalenko, D. N. Pogorelov, N. B. Yudina, A. N. Zaychikov, R. R. Bayramgulov, D. L. Sakun, L. M. Minkina, E. P. Matsekha, N. V. Tsyrenova, E. N. Grishina, M. V. Borisova, A. F. Matytsyn, T. B. Fedorova, Yu. V. Dinikina, V. V. Martynenko, A. P. Shapochnik, I. M. Yunusova, V. A. Mitrofanov, A. A. Rumyantsev, I. V. Fisyun, V. N. Timofeeva, A. V. Shamin, A. M. Markovsky, G. V. Bykova, N. A. Popova, N. V. Kochukova, E. A. Ostanina, A. A. Pshenichnikova, О. Г. Желудкова, Л. В. Ольхова, М. В. Рыжова, Л. В. Шишкина, Ю. В. Кушель, А. Г. Меликян, С. К. Горелышев, А. В. Голанов, Ю. Ю. Трунин, Н. А. Воробьёв, Н. А. Плахотина, К. Ф. Бойко, А. С. Левашов, О. Б. Полушкина, Д. Ю. Корнеев, Т. В. Постникова, И. Д. Бородина, А. Н. Кисляков, Д. А. Скобеев, С. В. Горбатых, С. С. Озеров, Е. В. Скоробогатова, Е. В. Инюшкина, В. Е. Попов, М. В. Мушинская, С. Г. Коваленко, Д. Н. Погорелов, Н. Б. Юдина, А. Н. Зайчиков, Р. Р. Байрамгулов, Д. Л. Сакун, Л. М. Минкина, Е. П. Мацеха, Н. В. Цыренова, Е. Н. Гришина, М. В. Борисова, А. Ф. Матыцын, Т. Б. Федорова, Ю. В. Диникина, В. В. Мартыненко, А. П. Шапочник, И. М. Юнусова, В. А. Митрофанов, А. А. Румянцев, И. В. Фисюн, В. Н. Тимофеева, А. В. Шамин, А. М. Марковский, Г. В. Быкова, Н. А. Попова, Н. В. Кочукова, Е. А. Останина, А. А. Пшеничникова

المساهمون: The team of authors expresses their sincere gratitude to doctors of the Pediatric Radiation Therapy Department of the Russian Scientific Center of Roentgenoradiology, Ministry of Health of Russia: O.I. Shcherbenko, N.I. Zelinskaya, R.A. Parkhomenko, A.M. Kryanev, O.S. Regentova, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia: A.V. Nechesnyuk, A.Kh. Tedeeva, N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia: I.V. Glekov, V.A. Grigorenko, as well as Professor A.G. Korshunov (Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center (DKFZ), Department of Neuropathology, Heidelberg University Hospital, German Cancer Consortium (DKTK), Heidelberg, Germany). The study was performed without external funding., Коллектив авторов выражает искреннюю признательность врачам детского отделения лучевой терапии ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России: О.И. Щербенко, Н.И. Зелинской, Р.А. Пархоменко, А.М. Кряневу, О.С. Регентовой, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России: А.В. Нечеснюку, А.Х. Тедеевой, ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России: И.В. Глекову, В.А. Григоренко, а также профессору А.Г. Коршунову (Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center (DKFZ), Department of Neuropathology, Heidelberg University Hospital, German Cancer Consortium (DKTK), Heidelberg, Germany). Исследование проведено без спонсорской поддержки.

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 3 (2023); 22-40 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 3 (2023); 22-40 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: прогностические факторы, medulloblastoma, WNT molecular group, treatment outcomes, survival, prognostic factors, медуллобластома, молекулярная группа WNT, результаты лечения, выживаемость

وصف الملف: application/pdf

العلاقة: https://journal.nodgo.org/jour/article/view/960/844Test; Ostrom Q.T., CioffiG., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–iii105. doi:10.1093/neuonc/noab200.; Johnston D.L., Keene D., Strother D., Taneva M., Lafay-Cousin L., Fryer C., Scheinemann K., Carret A.S., Fleming A., Afzal S., Wilson B., Bowes L., Zelcer S., Mpofu C., Silva M., Larouche V., Brossard J., Bouff et E. Survival Following Tumor Recurrence in Children With Medulloblastoma. J Pediatr Hematol Oncol. 2018;40(3):e159–e163. doi:10.1097/MPH.0000000000001095.; Chintagumpala M., Gajjar A. Brain tumors. Pediatr Clin North Am. 2015;62(1):167–78. doi:10.1016/j.pcl.2014.09.011.; Onodera S., Nakamura Y., Azuma T. Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. Int J Mol Sci. 2020;21(20):7559. doi:10.3390/ijms21207559.; Langenberg K.P.S., Meister M.T., Bakhuizen J.J., Boer J.M., van Eijkelenburg N.K.A., Hulleman E., Ilan U., Looze E.J., Dierselhuis M.P., van der Lugt J., Breunis W., Schild L.G., Ober K., van Hooff S.R., Scheijde-Vermeulen M.A., Hiemcke-Jiwa L.S., Flucke U.E., Kranendonk M.E.G., Wesseling P., Sonneveld E., Punt S., Boltjes A., van Dijk F., Verwiel E.T.P., Volckmann R., Hehir-Kwa J.Y., Kester L.A., Koudijs M.M.J., Waanders E., Holstege F.C.P., Vormoor H.J., Hoving E.W., van Noesel M.M., Pieters R., Kool M., Stumpf M., Blattner-Johnson M., Balasubramanian G.P., Van Tilburg C.M., Jones B.C., Jones D.T.W., Witt O., Pfister S.M., Jongmans M.C.J., Kuiper R.P., de Krijger R.R., Wijnen M.H.W., den Boer M.L., Zwaan C.M., Kemmeren P., Koster J., Tops B.B.J., Goemans B.F., Molenaar J.J. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'. Eur J Cancer. 2022;175:311–25. doi:10.1016/j.ejca.2022.09.001.; Schroeder K., Gururangan S. Molecular variants and mutations in medulloblastoma. Pharmgenomics Pers Med. 2014;7:43–51. doi:10.2147/PGPM.S38698.; Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., Soffietti R., von Deimling A., Ellison D.W. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. doi:10.1093/neuonc/noab106.; Kram D.E., Henderson J.J., Baig M., Chakraborty D., Gardner M.A., Biswas S., Khatua S. Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics. Bioengineering (Basel). 2018;5(4):78. doi:10.3390/bioengineering5040078.; Eberhart C.G., Tihan T., Burger P.C. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol. 2000;59(4):333–7. doi:10.1093/jnen/59.4.333.; Fattet S., Haberler C., Legoix P., Varlet P., Lellouch-Tubiana A., Lair S., Manie E., Raquin M.A., Bours D., Carpentier S., Barillot E., Grill J., Doz F., Puget S., Janoueix-Lerosey I., Delattre O. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol. 2009;218(1):86–94. doi:10.1002/path.2514.; Dahmen R.P., Koch A., Denkhaus D., Tonn J.C., Sörensen N., Berthold F., Behrens J., Birchmeier W., Wiestler O.D., Pietsch T. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 2001;61(19):7039–43. PMID: 11585731.; Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., Kleihues P., Ohgaki H. APC mutations in sporadic medulloblastomas. Am J Pathol. 2000;156(2):433–7. doi:10.1016/S0002-9440(10)64747-5.; Koch A., Hrychyk A., Hartmann W., Waha A., Mikeska T., Waha A., Schüller U., Sörensen N., Berthold F., Goodyer C.G., Wiestler O.D., Birchmeier W., Behrens J., Pietsch T. Mutations of the WNT antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer. 2007;121(2):284–91. doi:10.1002/ijc.22675.; Shih D.J., Northcott P.A., Remke M., Korshunov A., Ramaswamy V., Kool M., Luu B., Yao Y., Wang X., Dubuc A.M., Garzia L., Peacock J., Mack S.C., Wu X., Rolider A., Morrissy A.S., Cavalli F.M., Jones D.T., Zitterbart K., Faria C.C., Schüller U., Kren L., Kumabe T., Tominaga T., Shin Ra Y., Garami M., Hauser P., Chan J.A., Robinson S., Bognár L., Klekner A., Saad A.G., Liau L.M., Albrecht S., Fontebasso A., Cinalli G., De Antonellis P., Zollo M., Cooper M.K., Thompson R.C., Bailey S., Lindsey J.C., Di Rocco C., Massimi L., Michiels E.M., Scherer S.W., Phillips J.J., Gupta N., Fan X., Muraszko K.M., Vibhakar R., Eberhart C.G., Fouladi M., Lach B., Jung S., Wechsler-Reya R.J., Fèvre-Montange M., Jouvet A., Jabado N., Pollack I.F., Weiss W.A., Lee J.Y., Cho B.K., Kim S.K., Wang K.C., Leonard J.R., Rubin J.B., de Torres C., Lavarino C., Mora J., Cho Y.J., Tabori U., Olson J.M., Gajjar A., Packer R.J., Rutkowski S., Pomeroy S.L., French P.J., Kloosterhof N.K., Kros J.M., Van Meir E.G., Cliff ord S.C., Bourdeaut F., Delattre O., Doz F.F., Hawkins C.E., Malkin D., Grajkowska W.A., Perek-Polnik M., Bouff et E., Rutka J.T., Pfister S.M., Taylor M.D. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32(9):886–96. doi:10.1200/JCO.2013.50.9539.; Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., Groebner S., Grund K.B., Brugières L., Jones D.T.W., Pajtler K.W., Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., MacDonald T.J., Hernáiz Driever P., Bendel A.E., Bowers D.C., McCowage G., Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., Wesenberg F., Feychting M., Lannering B., Schüz J., Johansen C., Andersen T.V., Röösli M., Kuehni C.E., Grotzer M., Kjaerheim K., Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785–98. doi:10.1016/S1470-2045(18)30242-0.; Goschzik T., ZurMühlen A., Kristiansen G., Haberler C., Stefanits H., Friedrich C., von Hoff K., Rutkowski S., Pfister S.M., Pietsch T. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect WNT activated tumours. Neuropathol Appl Neurobiol. 2015;41(2):135–44. doi:10.1111/nan.12161.; Kool M., Korshunov A., Remke M., Jones D.T., Schlanstein M., Northcott P.A., Cho Y.J., Koster J., Schouten-van Meeteren A., van Vuurden D., Cliff ord S.C., Pietsch T., von Bueren A.O., Rutkowski S., McCabe M., Collins V.P., Bäcklund M.L., Haberler C., Bourdeaut F., Delattre O., Doz F., Ellison D.W., Gilbertson R.J., Pomeroy S.L., Taylor M.D., Lichter P., Pfister S.M. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–84. doi:10.1007/s00401-012-0958-8.; Cavalli F.M.G., Remke M., Rampasek L., Peacock J., Shih D.J.H., Luu B., Garzia L., Torchia J., Nor C., Morrissy A.S., Agnihotri S., Thompson Y.Y., Kuzan-Fischer C.M., Farooq H., Isaev K., Daniels C., Cho B.K., Kim S.K., Wang K.C., Lee J.Y., Grajkowska W.A., Perek-Polnik M., Vasiljevic A., Faure-Conter C., Jouvet A., Giannini C., Nageswara Rao A.A., Li K.K.W., Ng H.K., Eberhart C.G., Pollack I.F., Hamilton R.L., Gillespie G.Y., Olson J.M., Leary S., Weiss W.A., Lach B., Chambless L.B., Thompson R.C., Cooper M.K., Vibhakar R., Hauser P., van Veelen M.C., Kros J.M., French P.J., Ra Y.S., Kumabe T., López-Aguilar E., Zitterbart K., Sterba J., Finocchiaro G., Massimino M., Van Meir E.G., Osuka S., Shofuda T., Klekner A., Zollo M., Leonard J.R., Rubin J.B., Jabado N., Albrecht S., Mora J., Van Meter T.E., Jung S., Moore A.S., Hallahan A.R., Chan J.A., Tirapelli D.P.C., Carlotti C.G., Fouladi M., Pimentel J., Faria C.C., Saad A.G., Massimi L., Liau L.M., Wheeler H., Nakamura H., Elbabaa S.K., Perezpeña-Diazconti M., Chico Ponce de León F., Robinson S., Zapotocky M., Lassaletta A., Huang A., Hawkins C.E., Tabori U., Bouff et E., Bartels U., Dirks P.B., Rutka J.T., Bader G.D., Reimand J., Goldenberg A., Ramaswamy V., Taylor M.D. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31(6):737–54.e6. doi:10.1016/j.ccell.2017.05.005.; Goschzik T., ZurMuehlen A., Doerner E., Waha A., Friedrich C., Hau P., Pietsch T. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups. J Neuropathol Exp Neurol. 2021;80(5):419–30. doi:10.1093/jnen/nlab020.; Cliff ord S.C., Lannering B., Schwalbe E.C., Hicks D., O’Toole K., Nicholson S.L., Goschzik T., Zur Mühlen A., Figarella-Branger D., Doz F., Rutkowski S., Gustafsson G., Pietsch T.; SIOP-Europe PNET Group. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget. 2015;6(36):38827–39. doi:10.18632/oncotarget.5149.; Sabel M., Fleischhack G., Tippelt S., Gustafsson G., Doz F., Kortmann R., Massimino M., Navajas A., von Hoff K., Rutkowski S., Warmuth-Metz M., Cliff ord S.C., Pietsch T., Pizer B., Lannering B.; SIOP-E Brain Tumour Group. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129(3):515–24. doi:10.1007/s11060-016-2202-1.; Gottardo N.G., Hansford J.R., McGlade J.P., Alvaro F., Ashley D.M., Bailey S., Baker D.L., Bourdeaut F., Cho Y.-J., Clay M., Cliff ord S.C., Cohn R.J., Cole C.H., Dallas P.B., Downie P., Doz F., Ellison D.W., Endersby R., Fisher P.G., Hassall T., Heath J.A., Hii H.L., Jones D.T.W., Junckerstorff R., Kellie S., Kool M., Kotecha R.S., Lichter P., Laughton S.J., Lee S., McCowage G., Northcott P.A., Olson J.M., Packer R.J., Pfister S.M., Pietsch P.T., Pizer B., Pomeroy S.L., Remke M., Robinson G.W., Rutkowski S., Schoep T., Shelat A.A., Stewart C.F., Sullivan M., Taylor M.D., Wainwright B., Walwyn T., Weiss W.A., Williamson D., Gajjar A. Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014;127(2):189–201. doi:10.1007/s00401-013-1213-7.; Ramaswamy V., Remke M., Bouff et E., Bailey S., Cliff ord S.C., Doz F., Kool M., Dufour C., Vassal G., Milde T., Witt O., von Hoff K., Pietsch T., Northcott P.A., Gajjar A., Robinson G.W., Padovani L., André N., Massimino M., Pizer B., Packer R., Rutkowski S., Pfister S.M., Taylor M.D., Pomeroy S.L. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821–31. doi:10.1007/s00401-016-1569-6.; Dietzsch S., Placzek F., Pietschmann K., von Bueren A.O., Matuschek C., Glück A., Guckenberger M., Budach V., Welzel J., Pöttgen C., Schmidberger H., Heinzelmann F., Paulsen F., Escudero M.P., Schwarz R., Hornung D., Martini C., Grosu A.L., Stueben G., Jablonska K., Dunst J., Stranzl-Lawatsch H., Dieckmann K., Timmermann B., Pietsch T., Warmuth-Metz M., Bison B., Kwiecien R., Benesch M., Gerber N.U., Grotzer M.A., Pfister S.M., Cliff ord S.C., von Hoff K., Klagges S., Rutkowski S., Kortmann R.D., Mynarek M. Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. Adv Radiat Oncol. 2020;5(6):1158–69. doi:10.1016/j.adro.2020.09.018.; Gajjar A., Robinson G.W., Smith K.S., Lin T., Merchant T.E., Chintagumpala M., Mahajan A., Su J., Bouff et E., Bartels U., Schechter T., Hassall T., Robertson T., Nicholls W., Gururangan S., Schroeder K., Sullivan M., Wheeler G., Hansford J.R., Kellie S.J., McCowage G., Cohn R., Fisher M.J., Krasin M.J., Stewart C.F., Broniscer A., Buchhalter I., Tatevossian R.G., Orr B.A., Neale G., Klimo P. Jr, Boop F., Srinivasan A., Pfister S.M., Gilbertson R.J., Onar-Thomas A., Ellison D.W., Northcott P.A. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021;39(7):822–35. doi:10.1200/JCO.20.01372.; Michalski J.M., Janss A.J., Vezina L.G., Smith K.S., Billups C.A., Burger P.C., Embry L.M., Cullen P.L., Hardy K.K., Pomeroy S.L., Bass J.K., Perkins S.M., Merchant T.E., Colte P.D., Fitzgerald T.J., Booth T.N., Cherlow J.M., Muraszko K.M., Hadley J., Kumar R., Han Y., Tarbell N.J., Fouladi M., Pollack I.F., Packer R.J., Li Y., Gajjar A., Northcott P.A. Children’s Oncology Group Phase III Trial of ReducedDose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol. 2021;39(24):2685–97. doi:10.1200/JCO.20.02730.; Bueren A.O., Kortmann R.-D., Hoff K., Friedrich C., Mynarek M., Muller K., Goschzik T., Muhlen A., Gerber N., Warmuth-Metz M., Soerensen N., Deinlein F., Benesch M., Zwiener I., Kwiecien R., Faldum A., Bode U., Fleischhack G., Hovestadt V., Kool M., Jones D., Northcott P., Kuehl J., Pfister S., Pietsch T., Rutkowski S. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016;34(34):4151–60. doi:10.1200/JCO.2016.67.2428.; Michiels E.M.C., Schouten-Van Meeteren A.Y.N., Doz F., Janssens G.O., van Dalen E.C. Chemotherapy for children with medulloblastoma (Review). Cochrane Database Syst Rev. 2015;1:CD006678. doi:10.1002/14651858.CD006678.pub2.; Dhall G., O’Neil S.H., Ji L., Haley K., Whitaker A.M., Nelson M.D., Gilles F., Gardner S.L., Allen J.C., Cornelius A.S., Pradhan K., Garvin J.H., Olshefski R.S., Hukin J., Comito M., Goldman S., Atlas M.P., Walter A.W., Sands S., Sposto R., Finlay J.L. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on “Head Start” III: a multi-institutional, prospective clinical trial. Neuro Oncol. 2020;22(12):1862–72. doi:10.1093/neuonc/noaa102.; Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L.E., Merchant T.E., Woo S., Wheeler G., Ahern V., Krasin M.J., Fouladi M., Broniscer A., Krance R., Hale G.A., Stewart C.F., Dauser R., Sanford R.A., Fuller C., Lau C., Boyett J.M., Wallace D., Gilbertson R.J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–20. doi:10.1016/S1470-2045(06)70867-1. Erratum in: Lancet Oncol. 2006;7(10):797.; Zhukova N., Ramaswamy V., Remke M., Pfaff E., Shih D.J., Martin D.C., Castelo-Branco P., Baskin B., Ray P.N., Bouff et E., von Bueren A.O., Jones D.T., Northcott P.A., Kool M., Sturm D., Pugh T.J., Pomeroy S.L., Cho Y.J., Pietsch T., Gessi M., Rutkowski S., Bognar L., Klekner A., Cho B.K., Kim S.K., Wang K.C., Eberhart C.G., Fevre-Montange M., Fouladi M., French P.J., Kros M., Grajkowska W.A., Gupta N., Weiss W.A., Hauser P., Jabado N., Jouvet A., Jung S., Kumabe T., Lach B., Leonard J.R., Rubin J.B., Liau L.M., Massimi L., Pollack I.F., Shin Ra Y., Van Meir E.G., Zitterbart K., Schüller U., Hill R.M., Lindsey J.C., Schwalbe E.C., Bailey S., Ellison D.W., Hawkins C., Malkin D., Cliff ord S.C., Korshunov A., Pfister S., Taylor M.D., Tabori U. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927–35. doi:10.1200/JCO.2012.48.5052.; Nobre L., Zapotocky M., Khan S., Fukuoka K., Fonseca A., McKeown T., Sumerauer D., Vicha A., Grajkowska W.A., Trubicka J., Li K.K.W., Ng H.K., Massimi L., Lee J.Y., Kim S.K., Zelcer S., Vasiljevic A., Faure-Conter C., Hauser P., Lach B., van Veelen-Vincent M.L., French P.J., Van Meir E.G., Weiss W.A., Gupta N., Pollack I.F., Hamilton R.L., Nageswara Rao A.A., Giannini C., Rubin J.B., Moore A.S., Chambless L.B., Vibhakar R., Ra Y.S., Massimino M., McLendon R.E., Wheeler H., Zollo M., Ferruci V., Kumabe T., Faria C.C., Sterba J., Jung S., López-Aguilar E., Mora J., Carlotti C.G., Olson J.M., Leary S., Cain J., Krskova L., Zamecnik J., Hawkins C.E., Tabori U., Huang A., Bartels U., Northcott P.A., Taylor M.D., Yip S., Hansford J.R., Bouff et E., Ramaswamy V. Pattern of Relapse and Treatment Response in WNTActivated Medulloblastoma. Cell Rep Med. 2020;1(3):100038. doi:10.1016/j.xcrm.2020.100038.; Leary S.E.S., Packer R.J., Li Y., Billups C.A., Smith K.S., Jaju A., Heier L., Burger P., Walsh K., Han Y., Embry L., Hadley J., Kumar R., Michalski J., Hwang E., Gajjar A., Pollack I.F., Fouladi M., Northcott P.A., Olson J.M. Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children’s Oncology Group. JAMA Oncol. 2021;7(9):1313–21. doi:10.1001/jamaoncol.2021.2224.; Mani S., Chatterjee A., Dasgupta A., Shirsat N., Epari S., Chinnaswamy G., Gupta T. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go? Oncotarget. 2023;14:105–10. doi:10.18632/oncotarget.28360.; Capper D., Jones D.T.W., Sill M., Hovestadt V., Schrimpf D., Sturm D., Koelsche C., Sahm F., Chavez L., Reuss D.E., Kratz A., Wefers A.K., Huang K., Pajtler K.W., Schweizer L., Stichel D., Olar A., Engel N.W., Lindenberg K., Harter P.N., Braczynski A.K., Plate K.H., Dohmen H., Garvalov B.K., Coras R., Hölsken A., Hewer E., Bewerunge-Hudler M., Schick M., Fischer R., Beschorner R., Schittenhelm J., Staszewski O., Wani K., Varlet P., Pages M., Temming P., Lohmann D., Selt F., Witt H., Milde T., Witt O., Aronica E., Giangaspero F., Rushing E., Scheurlen W., Geisenberger C., Rodriguez F.J., Becker A., Preusser M., Haberler C., Bjerkvig R., Cryan J., Farrell M., Deckert M., Hench J., Frank S., Serrano J., Kannan K., Tsirigos A., Brück W., Hofer S., Brehmer S., Seiz-Rosenhagen M., Hänggi D., Hans V., Rozsnoki S., Hansford J.R., Kohlhof P., Kristensen B.W., Lechner M., Lopes B., Mawrin C., Ketter R., Kulozik A., Khatib Z., Heppner F., Koch A., Jouvet A., Keohane C., Mühleisen H., Mueller W., Pohl U., Prinz M., Benner A., Zapatka M., Gottardo N.G., Driever P.H., Kramm C.M., Müller H.L., Rutkowski S., von Hoff K., Frühwald M.C., Gnekow A., Fleischhack G., Tippelt S., Calaminus G., Monoranu C.M., Perry A., Jones C., Jacques T.S., Radlwimmer B., Gessi M., Pietsch T., Schramm J,. Schackert G., Westphal M., Reifenberger G., Wesseling P., Weller M., Collins V.P., Blümcke I., Bendszus M., Debus J., Huang A., Jabado N., Northcott P.A., Paulus W., Gajjar A., Robinson G.W., Taylor M.D., Jaunmuktane Z., Ryzhova M., Platten M., Unterberg A., Wick W., Karajannis M.A., Mittelbronn M., Acker T., Hartmann C., Aldape K., Schüller U., Buslei R., Lichter P., Kool M., Herold-Mende C., Ellison D.W., Hasselblatt M., Snuderl M., Brandner S., Korshunov A., von Deimling A., Pfister S.M. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–74. doi:10.1038/nature26000.; Chang C.H., Housepian E.M., Herbert C. Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969;93(6):1351–9. doi:10.1148/93.6.1351.; Goschzik T., Mynarek M., Doerner E., Schenk A., Spier I,. Warmuth-Metz M., Bison B., Obrecht D., Struve N., Kortmann R.D., Schmid M., Aretz S., Rutkowski S., Pietsch T. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas. Acta Neuropathol. 2022;144(6):1143–56. doi:10.1007/s00401-022-02505-5.; Thompson E.M., Hielscher T., Bouff et E., Remke M., Luu B., Gururangan S., McLendon R.E., Bigner D.D., Lipp E.S., Perreault S. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17(4):484–95. doi:10.1016/S1470-2045(15)00581-1.; Richardson S., Hill R.M., Kui C., Lindsey J.C., Grabovksa Y., Keeling C., Pease L., Bashton M., Crosier S., Vinci M., André N., Figarella-Branger D., Hansford J.R., Lastowska M., Zakrzewski K., Jorgensen M., Pickles J.C., Taylor M.D., Pfister S.M., Wharton S.B., Pizer B., Michalski A., Joshi A., Jacques T.S., Hicks D., Schwalbe E.C., Williamson D., Ramaswamy V., Bailey S., Cliff ord S.C. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro Oncol. 2022;24(1):153–65. doi:10.1093/neuonc/noab178.; https://journal.nodgo.org/jour/article/view/960Test

الإتاحة: https://doi.org/10.21682/2311-1267-2023-10-3-22-40Test
https://doi.org/10.1093/neuonc/noab200Test
https://doi.org/10.1097/MPH.0000000000001095Test
https://doi.org/10.1016/j.pcl.2014.09.011Test
https://doi.org/10.3390/ijms21207559Test
https://doi.org/10.1016/j.ejca.2022.09.001Test
https://doi.org/10.2147/PGPM.S38698Test
https://doi.org/10.1093/neuonc/noab106Test
https://doi.org/10.3390/bioengineering5040078Test
https://doi.org/10.1093/jnen/59.4.333Test

المؤلفون: Sarah Saxena, Christopher Rodts, Vincent Nuyens, Juliette Lazaron, Victoria Sosnowski, Franck Verdonk, Laurence Seidel, Adelin Albert, Jean Boogaerts, Veronique Kruys, Mervyn Maze, Joseph Vamecq

المصدر: BMC Anesthesiology, Vol 20, Iss 1, Pp 1-9 (2020)

مصطلحات موضوعية: Inflammation, Perioperative neurocognitive disorders, Cognition, Interleukin-6, High molecular group box 1, Anesthesiology, RD78.3-87.3

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12871-020-01200-wTest; https://doaj.org/toc/1471-2253Test

الوصول الحر: https://doaj.org/article/583d076ad81a4753bbbefb6ddfa08aa0Test

المؤلفون: Gabriel Chun-Hei Wong, Kay Ka-Wai Li, Wei-Wei Wang, Anthony Pak-Yin Liu, Queenie Junqi Huang, Aden Ka-Yin Chan, Manix Fung-Man Poon, Nellie Yuk-Fei Chung, Queenie Hoi-Wing Wong, Hong Chen, Danny Tat Ming Chan, Xian-Zhi Liu, Ying Mao, Zhen-Yu Zhang, Zhi-Feng Shi, Ho-Keung Ng

المصدر: Acta Neuropathologica Communications, Vol 8, Iss 1, Pp 1-14 (2020)

مصطلحات موضوعية: Adult medulloblastoma, Molecular group, Targeted sequencing, TP53, MYC, KMT2C, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s40478-020-01066-6Test; https://doaj.org/toc/2051-5960Test

الوصول الحر: https://doaj.org/article/e23ed8382f864108a4c0b654e679d523Test

المؤلفون: Margarita Zaytseva, Ludmila Papusha, Galina Novichkova, Alexander Druy

المصدر: Cancers; Volume 13; Issue 19; Pages: 4954

مصطلحات موضوعية: ependymoma, risk stratification, molecular group, prognosis

وصف الملف: application/pdf

العلاقة: Pediatric Oncology; https://dx.doi.org/10.3390/cancers13194954Test

الإتاحة: https://doi.org/10.3390/cancers13194954Test

المؤلفون: Gabriel Chun-Hei Wong (9625625), Kay Ka-Wai Li (9452402), Wei-Wei Wang (1626301), Anthony Pak-Yin Liu (9625628), Queenie Junqi Huang (9625631), Aden Ka-Yin Chan (9625634), Manix Fung-Man Poon (9625637), Nellie Yuk-Fei Chung (9625640), Queenie Hoi-Wing Wong (9625643), Hong Chen (108084), Danny Tat Ming Chan (9625646), Xian-Zhi Liu (9625649), Ying Mao (107082), Zhen-Yu Zhang (458621), Zhi-Feng Shi (9625652), Ho-Keung Ng (5659465)

مصطلحات موضوعية: Genetics, Adult medulloblastoma, Molecular group, Targeted sequencing, TP53, MYC, KMT2C

العلاقة: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Clinical_and_mutational_profiles_of_adult_medulloblastoma_groups/13219301Test

الإتاحة: https://doi.org/10.6084/m9.figshare.13219301.v1Test